Boston Scientific Corporation Q2 FY26 Earnings Analysis

- Full year 2026 organic revenue growth guidance: 6.5% to 8.0% (Page 5). - Second quarter 2026 organic revenue growth guidance: 5.0% to 7.0% (Page 5). - WATCHMAN global growth expected at mid-teens in 2026; U.S. WATCHMAN growth low to mid-teens with international growth over 20% (Page 12). - EP business organic sales grew 22% in Q1, with continued strong growth internationally; 2026 global EP anticipated growth around 10% (Page 4). - Urology full year organic growth expected low to mid-single digits due to challenges early in the year, but anticipated improvement as the year progresses (Page 4). - MedSurg expected to be slightly lighter in 2026 but improving into 2027 (Page 10). - WATCHMAN stand-alone cases expected to improve gradually through 2026 (Page 12). - Long-term outlook remains confident with potential for stronger growth in 2027 (Pages 11-12).

- Full year 2026 adjusted EPS guidance is $3.34 to $3.41, representing 9% to 11% growth versus 2025. - Q2 2026 adjusted EPS expected to be $0.82 to $0.84. - Adjusted operating margin expansion of 50 to 75 basis points anticipated for full year 2026. - Gross margins expected to be slightly lower than 2025 due to lower mix benefits and increased investments. - Company driving cost efficiencies with strict spend controls, AI automation, and organizational optimizations. - Confident in delivering double-digit EPS growth over the Long-Range Plan (LRP) period despite some sales pressure. - Revenue growth guidance revised to 6.5% to 8% operational and organic growth for full year 2026 (7.0% to 8.5% reported). - Margin improvement of about 150 basis points projected throughout the LRP, with focus on disciplined execution.

- Boston Scientific recently closed the acquisition of Valencia Technologies to complement its Urology business. - They expect the announced acquisition of Penumbra to close in the second half of 2026, which is a significant strategic investment. - The company is making commercial investments, particularly focused on WATCHMAN, EP, and other key product lines. - Investment in R&D continues with a strong pipeline, including next-generation catheters and mapping technology (e.g., FARAPULSE, FANAFLEX). - Capital expenditures in Q1 2026 were $177 million, with a focus on operating activities and efficiency initiatives. - They plan to maintain strategic tuck-in M&A as a top capital allocation priority, followed by share repurchases. - Supply chain and quality system investments are ongoing, contributing to adjusted gross margin pressures. - Full year 2026 free cash flow is expected to be approximately $4 billion, supporting continued investments.

- As of March 31, 2026, Boston Scientific had $1.453 billion in cash on hand and a gross debt leverage ratio of 1.8x. - The company intends to fund a $2 billion share repurchase in Q2 2026 primarily through existing cash on hand and projected cash flow; no immediate new debt issuance was mentioned for this purpose. - The Penumbra acquisition (~$15 billion) is expected to close in H2 2026, but there is no explicit mention of raising new debt or equity to finance this deal in the provided pages. - The company highlights strategic tuck-in M&A as a top capital allocation priority, followed by share repurchase, but no announcements of new fundraising through debt or equity were disclosed. - Overall, no clear plans for new fundraising through debt or equity are indicated in the transcript up to Q2 2026.

The transcript does not specifically mention the current or expected orderbook or pending orders for Boston Scientific. However, relevant insights related to business momentum and outlook include: - Boston Scientific reported solid Q1 2026 organic sales growth of 9.4%, slightly below prior expectations. - The company guides Q2 2026 organic growth of 5% to 7%, reflecting increased competitive dynamics and transient challenges. - They expect full-year 2026 organic growth of 6.5% to 8.0%. - Confident in growth across key business units, including EP, WATCHMAN, and Interventional Oncology, with several new product launches planned. - Management expressed confidence in maintaining leadership and expanding commercial momentum, especially post-Penumbra acquisition. - Share repurchases of approximately $2 billion planned in Q2, signaling confidence in future prospects. No explicit figures or commentary on order backlog or pending orders were provided in the transcript.